AMERICAN SOCIETY OF CLINICAL ONCOLOGY

AbbVie submitted a Biologics License Application for Teliso-V, a first-in-class ADC targeting c-Met overexpressing NSCLC, based on Phase 2 LUMINOSITY trial data. If approved, Teliso-V would address unmet needs in NSCLC treatment, offering a new option for patients with poor prognosis.

AbbVie submits Biologics License Application to FDA for Teliso-V, an ADC targeting c-Met overexpression in previously treated nonsquamous NSCLC, supported by Phase 2 LUMINOSITY trial data.

FDA approves AstraZeneca's Tagrisso for unresectable, Stage III EGFR-mutated lung cancer, based on LAURA Phase III trial results showing 84% reduction in disease progression risk.

Osimertinib (Tagrisso) received FDA approval for unresectable stage III non–small cell lung cancer (NSCLC) with EGFR mutations, based on LAURA trial data showing significant benefits, including 39.1-month median progression-free survival.

GLP-1 agonists like semaglutide and tirzepatide are increasingly used for weight loss, including in breast cancer patients. A study at Memorial Sloan Kettering Cancer Center found that these drugs led to an average 5% weight loss in breast cancer patients, with more significant losses over time. The study, presented at the 2024 ASCO Annual Meeting, aimed to assess the impact of GLP-1 agonists on weight and potential breast cancer outcomes, though no significant associations were found due to the small cohort size. The findings suggest GLP-1 agonists could be useful in managing weight gain, a common adverse event in breast cancer patients, potentially improving long-term outcomes.

FDA approves osimertinib (Tagrisso) for locally advanced, unresectable stage III NSCLC after chemoradiotherapy, based on LAURA trial data showing 7-fold increase in median PFS to 39.1 months. Osimertinib indicated for EGFR exon 19 deletions or exon 21 L858R mutations.

The FDA approved osimertinib (Tagrisso) for stage III EGFR-mutated NSCLC not progressing after platinum-based chemoradiation, supported by the phase 3 LAURA trial showing significant PFS improvements.

FDA approves osimertinib for locally advanced, unresectable stage III EGFR-mutated NSCLC after chemoradiotherapy, based on phase 3 LAURA trial results showing 84% reduction in progression or death risk. Osimertinib's median PFS was 39.1 months vs 5.6 months for placebo, with 57% ORR vs 33% for placebo. The trial did not compare osimertinib with current immunotherapy standards.

A study released on World Cancer Research Day highlights the need for wider access to clinical trials, noting that despite $80 billion annual spending on R&D, less than 5% of cancer patients participate due to various barriers. The report, by Asia Society's Cure4Cancer, suggests leveraging technologies like liquid biopsy and expanding trial access in low- and middle-income countries. This call for global collaboration follows President Biden's launch of the Quad Cancer Moonshot.

Elevar Therapeutics resubmitted an NDA to the FDA for camrelizumab plus rivoceranib in unresectable HCC, following a CRL addressing manufacturing issues. The resubmission is supported by phase 3 CARES-310 trial data showing improved OS and PFS compared to sorafenib, with no new safety signals.